Skip to main content
Premium Trial:

Request an Annual Quote

Tasso Blood Collection Devices Available to Aptar Digital Health Patients

NEW YORK ­– Tasso will make its blood collection devices available to medical software firm Aptar Digital Health's end users under a collaboration announced on Tuesday.

Tasso's devices will be available to patients included in Aptar's clinical trials and real-world studies and to life science companies collaborating with Crystal Lake, Illinois-based Aptar to develop digital health solutions, including digital therapies, disease management platforms, and digital patient support programs, Aptar said in a statement.

Tasso+ and Tasso-M20 devices will be available to patients, the firm added. Tasso+ is a US Food and Drug Administration-cleared blood lancet that collects liquid whole-blood samples, while Tasso-M20 is a CE-marked device for collecting volumetrically controlled whole-blood samples.

Financial and other terms of the deal were not disclosed.

Seattle-based Tasso announced in February that it received CE marking for TassoOne Plus, an at-home high-volume liquid blood collection device for the self-collection of capillary blood samples. The company closed a $100 million Series B financing round in late 2021.